Perrigo (PRGO) Return on Capital Employed (2013 - 2026)
Perrigo's (PRGO) quarterly Return on Capital Employed came in at 21.23% in Q1 2026, down 2372.0% year-on-year from 0.93% in Q1 2025, and down 56.93% on a QoQ basis from 13.53% in Q4 2025.
Perrigo (PRGO) Return on Capital Employed (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Return on Capital Employed data on file, last reported at 21.23% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 2372.0% year-over-year to 21.23% in Q1 2026; TTM through Mar 2026 was 21.23%, a 2372.0% decrease from a year earlier, with the FY2025 full-year figure at 13.89%, down 1512.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 21.23%, down from 13.53% in the prior quarter.
- Over the last five years, Return on Capital Employed for PRGO reached as high as 5.18% in Q3 2022 and fell as low as 21.23% in Q1 2026.
- Historically, Return on Capital Employed has averaged 0.43% across 5 years, with a median of 1.2% in 2024.
- Across the five-year window, Return on Capital Employed soared 474 bps in 2022 and tumbled 2372 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 0.81% in 2022, then surged by 104 bps to 1.65% in 2023, then slipped by 27 bps to 1.2% in 2024, then slumped by 1224 bps to 13.53% in 2025, then tumbled by 57 bps to 21.23% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 21.23% in Q1 2026, 13.53% in Q4 2025, and 3.12% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | -21.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -21.23% |
| Dec 31, 2025 | -13.53% |
| Sep 27, 2025 | 3.12% |
| Jun 28, 2025 | 3.26% |
| Mar 29, 2025 | 2.49% |
| Dec 31, 2024 | 1.20% |
| Sep 28, 2024 | -0.18% |
| Jun 29, 2024 | -0.39% |
| Mar 30, 2024 | 0.52% |
| Dec 31, 2023 | 1.65% |
| Sep 30, 2023 | 2.01% |
| Jul 1, 2023 | 1.71% |
| Apr 1, 2023 | 1.07% |
| Dec 31, 2022 | 0.81% |
| Oct 1, 2022 | 0.97% |
| Jul 2, 2022 | 5.18% |
| Apr 2, 2022 | 4.04% |
| Dec 31, 2021 | 4.52% |
| Oct 2, 2021 | 4.43% |
| Jul 3, 2021 | 0.45% |